Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (November 2024)
41 slides from Defence Therapeutics Inc Class A's investor presentation, Nov 1, 2024
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q3 2024
Slide 2: Forward Looking Statements
Investor Presentation | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, includi
Slide 3: The Highlights
Investor Presentation | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Quebec, with an attractive capital structure and loyal investors. ● Patented, highly versatile, proprietary Accum® platform technology, which vastly improves any type of
Slide 4: Our Mandate
Our Mandate To overcome encountered intracellular barriers for almost any treatment directly applicable to: ● Protein/RNA/DNA vaccines ● Antibody-Drug Conjugates ● Radiopharmaceuticals and any type of biomedicine 4
Slide 5: Problem Driven Solutions for ADCs
5 Ineffective Treatments ● Radiation + chemotherapy can kill tumor cells but also healthy cells. ● Nuclear-targeted biopharmaceuticals struggle with molecular obstacles which has limited their possibility to become a therapeutic standard for human diseases (i.e. cancer). Problem Driven Solutions for
Slide 6: Platform Technology
eGFP-hGal3-Expressing DCs 10 µm Platform Technology antigen-x Accum antigen-x (Damaged endosomes triggered by Accum®) ACCUM® Technology is a proprietary and US patented platform technology, with proven enhanced We have tackled an industry-wide ADC challenge intracellular drug delivery. of Nuclear Lo
Slide 7: How We Do It
Investor Presentation | Defence Theurapeutics How We Do it ACCUM® promotes endosome-to-cytosol escape, by breaking down endosomal membranes. It can therefore be used in the context of: ● Protein or cell-based vaccines ● mRNA or DNA ● ADCs ● New entities with novel pharmacological properties 7
Slide 8: Technology: Turning ADC challenges into proven platform solutions
Investor Presentation | Defence Theurapeutics Technology Turning ADC challenges into proven platform solutions Potential Significance of Accum®Technology ACCUM Talk-Worthy Results ACCUM® Innovative Approach CURRENT POOR Accum® EFFICIENT ACCUMULATION ACCUMULATION Overcoming problematic cell recycling
Slide 9: Defence Therapeutics: Innovative Platform
Investor Presentation | Defence Theurapeutics Defence Therapeutics: Innovative Platform Accum® Molecule BILE ACID NLS Highly Versatile Technology Ideal for the development of Easily applicable to mRNA-DNA- Molecules with anti- Augments the anti-tumoral novel cell-based vaccines , or protein-based va
Slide 10: Global Market Pioneers
Investor Presentation | Defence Theurapeutics 13.8% CAGR from 2018 to 2025 vs. 3-6% for the global pharmaceuticals $526 Global Market Billion Pioneers This indicates GLOBAL BIOPHARMA At 17% of the global biopharmaceuticals are pharmaceutical market, destined to dominate the biopharma is projected to
Slide 11: Product Pipeline
PHASE 1- DISCOVERY PRE-CLINICAL CMC IND Filling 2024 Investor Presentation | Defence Theurapeutics PRODUCT INDICATION RESEARCH & NON-GLP GLP DEVELOPMENT Valuable Cell Vaccine Project Traction ARM-X Solid Tumors AccuTOX (Small molecule) AccuTOX-001 Melanoma AccuTOX-IN001 Lung Cancer Protein Vaccine A
Slide 12: Innovating Pathways to Success
Innovating Pathways First to develop a combined breakthrough, with Proprietary and versatile technology targeting Problem-driven solutions confirming strong market Exponential scaling potential, with fully owned assets to be capitalized to Success precision and efficient cell nucleus drug delivery.
Slide 13: Cancer Therapeutics
01 Cancer Therapeutics We are leveraging our Accum technology, to create novel immuno-oncology treatments. Through our ADC and AccuTOX, we have been specifically targeting Melanoma, Breast and Lung Cancers within Discovery and Preclinical work and have ADCs with improved bioaccumulation properties t
Slide 14: The AccuTOX Program
14 01 CANCER THERAPEUTICS The AccuTOX Program: Ready for Phase I in Canada, FDA clearance in the USA Indication: Melanoma 14
Slide 15: AccuTOX: An Accum Variant with Enhanced Killing Potency
Investor Presentation | Defence Theurapeutics AccuTOX®: An Accum® Variant with Enhanced killing Potency (~30 Fold Increase) ORIGINAL ACCUM AccuTOX-001 93% 100% 81% 100% 38% 100% 84% 100% 15
Slide 16: AccuTOX-001 Halts Tumor Development with Checkpoint Inhibitors
Investor Presentation | Defence Theurapeutics AccuTOX-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors Synergistic effect against ICI- resistant Tumors 16
Slide 17: AccuTOX-001 Phase Trial
Investor Presentation | Defence Theurapeutics AccuTOX-001 Phase 1 Trial: 3+3 Design (Phase I trial cleared by the FDA and Health Canada) Phase I/II A Phase II AccuTOX-001 + aPD-1 AccuTOX-001 + aPD-1/aLAG-3 Dose Escalation 3+3 Design Dose I AccuTOX-001 Dose II Selected Dose AccuTOX-001 AccuTOX-001 Do
Slide 18: AccuTOX/Anti-PD1 Intranasal Administration
Investor Presentation | Defence Theurapeutics AccuTOX/Anti-PD1 Intranasal Administration Greatly Reduces Lung Nodule Numbers PBS PD-1 AccuTOX AccuTOX PD-1 18
Slide 19: Vaccine Development
02 Vaccine Development State of the Art Facilities Laboratory space of 140 m2, accommodating 12 highly qualified personnel and a wide range of equipment. Access in process to 12 high tech platforms Accelerated Vaccine Development: located at the Institute for Research in Cancer & Infectious Diseases
Slide 20: Cancer Vaccines
Investor Presentation | Defence Theurapeutics 02 Cancer Vaccines We are leveraging our Accum® technology, to create novel immuno-oncology treatments. While studying AccuTOX®, the molecule was shown to elicit specific reprogramming event in mesenchymal stromal cells (MSCs). Therefore, it is used by D
Slide 21: Defence Arm-X Cancer Vaccine
21 02 CANCER VACCINES Defence Arm-X Cancer Vaccine The solution to cure any solid cancer tumors 21
Slide 22: The AccuTOX-Reprogrammed MSC (ARM-X) Cancer Vaccine
Investor Presentation | Defence Theurapeutics The AccuTOX®-Reprogrammed MSC (ARM-X) Cancer Vaccine Patient admission and tumor resection Cell Processing Center Patient Treatment AccuTOX®/ANTIGEN REPROGRAMMING Immune-suppressive MSCs ARM-X 22 Time required to generate the ARM-X vaccine: 24 h
Slide 23: ARM-X Pancreatic Cancer and B16 Melanoma Results
Investor Presentation | Defence Theurapeutics Pancreatic Cancer B16 Melanoma Ctl ARM-X PD-1 ARM-X + PD-1 1600 1000 PBS Tumor volume (mm3) Tumor Volume (mm3) Ctl PD-1 800 PD-1 1200 ARM-X ARM-X 600 ARM-X + PD-1 ARM-X + PD-1 800 MSC 400 400 MSC + PD-1 200 0 0 0 8 16 24 32 40 0 8 16 24 32 40 Timeline (D
Slide 24: ARM-X Phase I Trial in Canada & USA
Investor Presentation | Defence Theurapeutics ARM-X Phase I Trial in Canada & USA (planned for Q2 of 2025) Part A Part B ARM-X Monotherapy ARM-X + ePD-1 Dose Escalation (3+3 Design) Dose I Dose II Selected Dose Dose III 24
Slide 25: The ADC Program
25 01-A CANCER THERAPEUTICS The ADC Program: An example demonstrating how Accum can transform any ADC Indications: Ewing Sarcoma, Gastric Cancer, AML, Uveal Melanoma 25
Slide 26: Defence Improves ADCs Efficacy
Investor Presentation | Defence Theurapeutics Defence improves ADCs efficacy We are not developing novel ADC, we are making any ADCs in development 20, 50 or even 100X better 1) The Accum® platform amplifies the therapeutics potency of any given ADC by ensuring its enhanced accumulation with lower d
Slide 27: XXX-ADC: The Perfect Example
Investor Presentation | Defence Theurapeutics XXX-ADC: The perfect example An ADC developed by a European Biotech targeting endoglin (CD105). The ADC shows in vivo potency when used at 60 mg/kg - CD105 (TGF-beta co-receptor) is a membrane protein - Internalization capability - Strongly expressed in
Slide 28: XXX-ADC: The Perfect Example
Investor Presentation | Defence Theurapeutics XXX-ADC: The perfect example Once Accum® was conjugated onto this ADC, therapeutic potency could be achieved (60-fold enhancement) os e se se st d nd do d d o 1 n 1200 2 3 PBS Tumor volume (mm3) XXX-ADC (5 mg/kg) 800 XXX-ADC (1 mg/kg) Accum 1 (1 mg/kg) A
Slide 29: XXX-ADC: The Perfect Example
Investor Presentation | Defence Theurapeutics XXX-ADC: The perfect example Once Accum® was conjugated onto this ADC, therapeutic potency could be achieved (60-fold enhancement) 100 Probability of Survival 80 PBS XXX-ADC (5 mg/kg) 60 XXX-ADC (1 mg/kg) 40 Accum 1 (1 mg/kg) Accum 1 (5 mg/kg) 20 Accum 2
Slide 30: XXX-ADC: The Perfect Example
Investor Presentation | Defence Theurapeutics XXX-ADC: The perfect example Once Accum® was conjugated onto this ADC, therapeutic potency could be achieved (60-fold enhancement) se se os e st d o nd do n d d 1 2 3 28 PBS XXX-ADC (5 mg/kg) 26 XXX-ADC (1 mg/kg) Weight (g) 24 Accum 1 (1 mg/kg) Accum 1 (
Slide 31: The Radio-Immuno-Conjugates Program: Including the Orano partnership
31 01-A CANCER THERAPEUTICS The Radio-Immuno-Conjugates Program: Including the Orano partnership Indications: Ovarian & Solid Tumors 31
Slide 32: Radiation particle characteristics and DNA Damage
Radiation particle characteristics and DNA Damage: Particle Path Length DNA Damage
Slide 33: Efficacy of Auger Electron is proportional to DNA proximity
Efficacy of Auger Electron is proportional to DNA proximity and nuclear accumulation: Endosomal rupture Endosomal escape and NLS moieties
Slide 34: AccuTOX Synergic Cytotoxicity with Radioactivity
Investor Presentation | Defence Theurapeutics Defence’s AccuTOX® Synergic Cytotoxicity with Radioactivity: • AccuTOX induces dramatically ROS production • AccuTOX induces endosome escape • AccuTOX induces nuclear accumulation more efficiency • AccuTOX induces Immune Response (cytotoxic and humoral r
Slide 35: Orano Partnership: the AccuTRIC Project
Orano Partnership: the AccuTRIC Project: • To develop the next generation of RIC exploiting the therapeutic dependency of Auger electron emitter elements in closer proximity to nuclear DNA when combined with Defence’s AccuTOX to induce its nuclear accumulation • Agreement in place with the Canadian
Slide 36: The Protein Vaccine Program
36 02 CANCER VACCINES The Protein Vaccine Program Accum-E7: Cervical Cancer and Head & Neck Tumors 36
Slide 37: Accum-E7 Tumor Volume in Cervical Cancer Models
Investor Presentation | Defence Theurapeutics Assessment of tumor volume in animals with pre-establsihed cervical cancer treated with Accum-E7 Advanced Protein- based Vaccines Benefiting from the multiplier ability of Accum® (100x), Defence Therapeutics can easily direct the science from one antigen
Slide 38: Corporate: Management and Board of Directors
38 Corporate: Management and Board of Directors 38
Slide 39: Board Members, Advisors and Management
Investor Presentation | Defence Theurapeutics Board Members, Advisors and Management Sebastien Plouffe Dr. Philippe Lefrançois Chief Executive Officer, President & Director Director Financial expert and entrepreneur with 25+ years Director of Research in the dermatology experience with public compani
Slide 40: What Differentiates Defence Therapeutics?
Investor Presentation | Defence Therapeutics What Differentiates Defence Therapeutics? Accum Platform BILE ACID NLS Infinite number Possibility to generate Discovery of new of products hundreds of variants pharmacological properties Versatility 40
Slide 41: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com 1615 - 200 Burrard Street, Vancouver, BC, V6C 3L6 Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Defence Therapeutics — Investor Presentation (November 2024) on 6ix